In one paragraphArticle in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
9 authors.
Yuto KubotaDepartment of Neuropharmacology, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Chuo 409-3898, Japan.
Eiji ShigetomiDepartment of Neuropharmacology, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Chuo 409-3898, Japan.ORCID 0000-0002-5267-6155 Kozo SaitoDepartment of Neuropharmacology, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Chuo 409-3898, Japan.
Youichi ShinozakiDepartment of Neuropharmacology, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Chuo 409-3898, Japan.
Kenji KobayashiDepartment of Neuropharmacology, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Chuo 409-3898, Japan.ORCID 0000-0002-6830-6933 Masayoshi TanakaDepartment of Neuropharmacology, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Chuo 409-3898, Japan.ORCID 0009-0000-1222-7390 Bijay ParajuliDepartment of Neuropharmacology, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Chuo 409-3898, Japan.
Kenji F TanakaDivision of Brain Sciences, Institute for Advanced Medical Research, Keio University School of Medicine, Shinjuku, Tokyo 160-8582, Japan.
Schuichi KoizumiDepartment of Neuropharmacology, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Chuo 409-3898, Japan.ORCID 0000-0001-6184-3106 Funding
Japan Agency for Medical Research and Development JP20gm131000Japan Society for the Promotion of Science 18H05121, 20H05902, 21K19309, 21H04786, 23K18162 , 24H04786, JP16H06276 (AdAMS)University of Yamanashi GLIA Center grant
6 · The paper itselfAbstract
Alexander disease (AxD) is an intractable neurodegenerative disease caused by mutations in
Indexed as
Alexander DiseaseAstrocytesDisease Models, AnimalGlial Fibrillary Acidic ProteinMice, TransgenicAnimalsCalcium SignalingCells, CulturedMicePrimary Cell CultureGlial Fibrillary Acidic Proteincell-autonomous effectcultured astrocytesRosenthal fibers (RFs)
Identifiers
PMID39596168
PMCPMC11595037
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390